Capecitabine Tablet, Film Coated
Product Images NDC 67877-459

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Capecitabine (NDC 67877-459). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ascend Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Capecitabine 150mg 60tab

Label for Capecitabine 150 mg film-coated tablets, USP, oral use, manufactured by Alkem Laboratories Ltd. and distributed by Ascend Laboratories, LLC. The label states storage instructions, prescription status (Rx Only), and package quantity of 60 tablets. It includes the Ascend Laboratories logo and an NDC barcode.*

FDA Label Image

Capecitabine 500mg 120tab

Capecitabine Tablets, USP 500 mg film-coated oral tablets in a bottle label by Ascend Laboratories, LLC. The label states it contains 120 tablets, includes dosage guidelines, storage instructions to keep tightly closed at controlled room temperature, and notes manufacturing by Alkem Laboratories Ltd., India. A barcode and NDC number 67877-459-12 are also visible.*

FDA Label Image

Capecitabine Fig 1

A survival curve comparing Capecitabine and 5-FU + Leucovorin treatment groups, showing survival probability over months since randomization. The graph includes a risk table displaying patient numbers at different time points for each group. The solid line represents Capecitabine and the dashed line 5-FU + Leucovorin.*

FDA Label Image

Capecitabine Fig 2

A survival curve comparing treatment groups of Capecitabine versus 5-FU + Leucovorin over months since randomization. The graph shows survival probability on the vertical axis from 0.0 to 1.0, and time in months on the horizontal axis from 0 to 96. The solid line represents Capecitabine, and the dashed line represents 5-FU + Leucovorin, with a table below indicating number at risk for each group at various time points.*

FDA Label Image

Capecitabine Fig 3

A survival curve chart comparing estimated probability over time in days between two groups: patients treated with 5-FU + Leucovorin (Mayo Regimen) and those treated with Capecitabine Tablets 1250 mg/sqm twice daily intermittently. The y-axis represents estimated probability, and the x-axis represents time up to 1500 days. The chart includes an arrow marking around 391-392 days.*

FDA Label Image

Capecitabine Fig 4

A survival curve chart comparing estimated probability over time (days) for two treatment groups: Docetaxel 100 mg/sqm every 3 weeks (dashed line) and Capecitabine tablets 1250 mg twice daily intermittently with Docetaxel 75 mg/sqm every 3 weeks (solid line). The chart shows survival probabilities declining over approximately 700 days with median survival times marked at around 128 and 186 days.*

FDA Label Image

Capecitabine Fig 5

A Kaplan-Meier survival curve comparing estimated probability over time (days) between two treatment groups: Docetaxel 100 mg/sqm every 3 weeks and Capecitabine Tablets 1250 mg/sqm twice daily intermittent with Docetaxel 75 mg/sqm every 3 weeks. The plot shows survival probabilities declining over approximately 800 days with marked median survival times.*

FDA Label Image

Capecitabine Meta Path

An illustration diagram showing the metabolic pathway of Capecitabine to 5-FU. It includes chemical structures for Capecitabine, 5'-DFCR, 5'-DFUR, and 5-FU with arrows indicating enzymatic conversions via Carboxylesterase, Cyd deaminase, and dThdPase enzymes.*

FDA Label Image

Capecitabine Str

Chemical structure of capecitabine, showing its molecular arrangement including a fluorinated pyrimidine ring linked to a sugar moiety and a pentyl ester group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.